Medicines for Malaria Venture (MMV)
@mmv
A leading global health partnership working to reduce the burden of malaria. We discover, develop and deliver new antimalarial medicines.
Pregnant & breastfeeding women must be protected through clinical research, not from it. MMV & partners are calling for actionable guidance to support their inclusion in clinical research and generate robust evidence: bit.ly/4wLXBwa #WorldBreastfeedingWeek
Relapsing #malaria can cause repeated episodes of illness from a single mosquito bite. A new study from Papua New Guinea & Indonesia is helping build the evidence needed to introduce improved approaches into routine care. More: bit.ly/4fwLLOV
Congrats to MMV's André-Marie Tchouatieu, who was recognized for his visionary leadership in the fight against #malaria at Benin's La Nuit du Paludisme. The Exceptional Commitment Award celebrates his success in mobilizing minds, inspiring generations and saving countless lives.
MMV met with leaders from the Japan Institute for Health Security (JIHS) to discuss Japan's approach to #malaria and health security, showcase MMV's pipeline of innovative malaria medicines and explore opportunities for future collaboration.
Long-acting injectables could provide protection from malaria for up to 6 months with a single administration. Cristina Donini explains how it works. Reaching zero #malaria requires continued #innovation & sustained commitment to get breakthroughs to those who need them most.
From discovery to delivery, collaboration across the global malaria community underpins innovation and progress. Here are three ways Japan contributes to the fight against one of the world's deadliest diseases.
A single-dose cure for #malaria: one patient, one visit, one treatment, done. MMV’s Cristina Donini explains how it works. Reaching zero malaria requires continued #innovation and the sustained commitment to get the latest breakthroughs to the people who need them most.
Last week, representatives from the MMV/DNDi joint regulatory sciences platform and medical affairs met with the Ghana FDA at the Ghanaian Mission in Geneva to discuss how we can reinforce our shared commitment to closer regulatory collaboration.
MMV convened experts in clinical trials, immunology, modelling & machine learning to define the data needed to build AI-powered models of the immune response to #malaria. Learn more about 3 of our latest AI drug discovery and development partnerships: bit.ly/4yalrCN
From single-dose cures to long-acting injectables, next-gen #malaria tools could transform how the disease is prevented & treated. Today, MMV's Cristina Donini features in the Daily Express, photographed by Rankin for @malarianomoreuk.bsky.social's #FacesOfInnovation campaign: bit.ly/4woWi5v
EU ability to prevent, detect and respond to infectious diseases relies on global collaboration and thriving #innovation. In this joint paper with PDP partners, we highlight @globalhealthedctp3.bsky.social's role in Europe–Africa research, clinical development and access: bit.ly/4xKn21U
A new version of #MMVSola is now live 🔹 Dose prediction tools for LAIs 🔹 Enhanced interactive plots & tables 🔹 Improved models to better estimate drug properties 🔹 Built-in documentation & user guides Try it for free here: mmvsola.org
MMV’s Project of the Year 2025 is a powerful example of how we can go farther and faster by working together. This week, we convened the partners behind Coartem® Baby, the first #malaria treatment specifically designed for newborns and young infants: bit.ly/4en79Xw
Another milestone in the treatment of vivax #malaria. Thailand is the second country to approve paediatric tafenoquine, a single-dose treatment designed to help prevent relapse. Co-developed by MMV and GSK, pTQ can help children recover without the threat of repeated relapse.
MMV’s 9th African call for proposals is now open! We’re looking for projects that could help accelerate #malaria drug discovery, from assay development and AI-supported discovery to innovative biology and novel antimalarials. Apply by 29 August: bit.ly/3Rt1h6j
As #malaria becomes more complex, we need simpler tools. #Innovations like single-dose cures & long-acting injectables can accelerate elimination in complex settings. Because the best innovations are the ones people actually use. That’s what makes them elimination accelerators.
What does it take to move new health technologies from pilot projects into routine care? Last month in Thailand, MMV colleagues joined NMPs from across the Asia-Pacific to observe the implementation of tools for relapsing #malaria in real-world settings & exchange insights.
New #malaria tools are expanding what’s possible in prevention, treatment & elimination. But #innovation alone is not enough. How can countries accelerate access & delivery at scale & translate innovation into lasting impact? Join us tomorrow at #WHA79: bit.ly/4uFHONN
This week, MMV and @dndi.org drug discovery teams came together to exchange ideas, common challenges and lessons learned across our research. From prioritizing promising compounds to advancing research in endemic countries, shared learning helps strengthen global health #innovation.
British science is behind 1 in 5 tools in the antimalarial R&D pipeline. Sustaining investment in UK malaria research could accelerate progress towards #malaria elimination while generating ripple effects across global health and economic development: bit.ly/49vc8T5
Funding cuts, resistance, climate change and conflict are creating a perfect storm that threatens progress against #malaria. A new perspective paper co-authored by MMV’s George Jagoe explores what malaria research must prioritize next: bit.ly/4tjf9xb
At #RNPM26 in Brazil, MMV marked #WorldMalariaDay by discussing advances in tackling relapsing vivax #malaria. Brazil’s rollout of new tools like single-dose tafenoquine is helping redefine what’s possible for elimination.
Funding opportunity for women researchers in sub-Saharan Africa. 2026 L’Oréal-UNESCO For Women in Science Programme: • PhD & postdoc (SSA) • 30 PhD + 8 postdoc grants • €10k / €15k + leadership training Deadline: 15 May 2026 Apply: bit.ly/4cXDgv6
How are partnerships strengthening R&D capacity in Africa & what does this mean for #malaria? At a #WHSNairobi2026 side event, MMV & partners highlighted initiatives like RAFIKI, which is strengthening R&D in endemic countries while fostering new Africa/Europe collaborations. #WorldMalariaDay
United in the fight against #malaria and staying one step ahead of antimalarial drug resistance. Building on the momentum of #WorldMalariaDay, yesterday MMV and the RBM Partnership to End Malaria convened partners in Geneva to align and strengthen our collective response to drug resistance.
Progress against #malaria is accelerating, but the last mile is the hardest. In Bangkok, APMEN is convening 19 countries to share research and tools to advance elimination across the Asia Pacific. #WorldMalariaDay
#PressRelease Brazil is the first country to roll out paediatric tafenoquine, closing a critical gap in treating relapsing #malaria in children. Co-developed by MMV and GSK, this child-friendly formulation makes treatment easier to complete and helps prevent relapse.
